Search
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin is a progestin used as the progestational component of combined hormonal contraceptives. It is administered transdermally in combination with the estrogen ethinyl estradiol, delivering both hormones systemically over a 7-d...
Synonyms: D-Norgestrel 3-oximeCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEnclomiphene
go.drugbank.com/drugs/DB06735InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesPinacidil
go.drugbank.com/drugs/DB06762ApprovedThe above processes result in reduced blood pressure. This drug has been discontinued by the FDA.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsSuvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalLenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDifluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnDifluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersNorgestrel
go.drugbank.com/drugs/DB09389ApprovedNorgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only t...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center, it is considered a boronate proteasome inhibitor. More than 99% of the drug compound is the R-enantiomer. Ixazomib was a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOleandomycin
go.drugbank.com/drugs/DB11442ExperimentalVet approvedOleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors